Voya Investment Management LLC lowered its position in shares of AstraZeneca Plc (NYSE:AZN – Free Report) by 77.0% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 283,692 shares of the company’s stock after selling 949,903 shares during the quarter. Voya Investment Management LLC’s holdings in AstraZeneca were worth $46,160,000 as of its most recent SEC filing.
A number of other institutional investors also recently modified their holdings of the business. Amundi raised its position in shares of AstraZeneca by 6.7% in the second quarter. Amundi now owns 16,422,784 shares of the company’s stock valued at $3,114,088,000 after buying an additional 1,036,635 shares in the last quarter. Janus Henderson Group PLC grew its stake in AstraZeneca by 889.9% during the first quarter. Janus Henderson Group PLC now owns 11,949,424 shares of the company’s stock worth $2,319,947,000 after buying an additional 10,742,268 shares in the last quarter. Fisher Asset Management LLC lifted its holdings in shares of AstraZeneca by 3.2% during the 3rd quarter. Fisher Asset Management LLC now owns 11,501,748 shares of the company’s stock worth $1,857,187,000 after acquiring an additional 355,456 shares during the period. Royal Bank of Canada boosted its position in shares of AstraZeneca by 208.6% during the 1st quarter. Royal Bank of Canada now owns 10,386,455 shares of the company’s stock worth $2,048,417,000 after acquiring an additional 7,021,126 shares in the last quarter. Finally, Rathbones Group PLC raised its position in AstraZeneca by 106,772.0% during the first quarter. Rathbones Group PLC now owns 8,054,943 shares of the company’s stock valued at $1,560,419,000 after purchasing an additional 8,047,406 shares in the last quarter. Institutional investors own 20.35% of the company’s stock.
AstraZeneca Stock Performance
Shares of AstraZeneca stock opened at $175.34 on Friday. AstraZeneca Plc has a 1-year low of $153.41 and a 1-year high of $212.71. The company has a current ratio of 1.01, a quick ratio of 0.79 and a debt-to-equity ratio of 0.51. The business has a 50-day moving average price of $170.44 and a two-hundred day moving average price of $180.08. The company has a market cap of $271.94 billion, a P/E ratio of 24.80, a PEG ratio of 1.39 and a beta of 0.24.
AstraZeneca (NYSE:AZN – Get Free Report) last posted its quarterly earnings results on Saturday, October 31st. The company reported $2.79 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.60 by $0.19. AstraZeneca had a return on equity of 31.85% and a net margin of 17.68%. The firm had revenue of $16.21 billion for the quarter, compared to analysts’ expectations of $16 billion. During the same period in the prior year, the business earned $2.38 EPS. The company’s revenue for the quarter was up 6.5% compared to the same quarter last year. As a group, analysts anticipate that AstraZeneca Plc will post 10.22 EPS for the current year.
Wall Street Analyst Weigh In
Several analysts recently weighed in on the company. Citigroup reaffirmed a “buy” rating on shares of AstraZeneca in a research note on Tuesday, October 6th. Deutsche Bank upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research note on Tuesday, September 15th. CICC Research started coverage on AstraZeneca in a report on Sunday, August 23rd. They issued an “outperform” rating and a $198.00 target price for the company. Royal Bank Of Canada assumed coverage on AstraZeneca in a report on Tuesday, September 8th. They set an “outperform” rating on the stock. Finally, Wall Street Zen upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating in a research report on Saturday, October 31st. Sixteen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $206.67.
Read Our Latest Analysis on AstraZeneca
About AstraZeneca
AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries. AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.
See Also
- Five stocks we like better than AstraZeneca
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.
